Regional outbreak of community-associated methicillin-resistant Staphylococcus aureus ST834 in Japanese children.


Journal

BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551

Informations de publication

Date de publication:
09 Jan 2019
Historique:
received: 15 09 2018
accepted: 20 12 2018
entrez: 11 1 2019
pubmed: 11 1 2019
medline: 6 2 2019
Statut: epublish

Résumé

Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infection has recently become a challenging problem worldwide and in Japan. We experienced 10 pediatric patients infected with CA-MRSA and hospitalized from 2011 to 2014 in a tertiary care hospital in Saitama, Japan, and assessed the characteristic of the strains using a whole genome sequencing (WGS)-based approach. CA-MRSA strains isolated from infected patients who required hospitalization for treatment were evaluated in this study. Antimicrobial susceptibility tests, molecular typing by PCR and pulse-field gel electrophoresis (PFGE) were performed to characterize MRSA strains. WGS was performed for detailed genetic analysis. A total of 582 MRSA strains (35.2%) were identified among 1625 S. aureus strains collected during the study period. Ten MRSA strains (1.7%) were defined as CA-MRSA clinically, and all were isolated from pediatric patients. All strains mainly caused purulent lymphadenitis, were susceptible to fluoroquinolone and tetracycline, exhibited sequence type (ST) 834 or its single-locus variants and contained staphylococcal cassette chromosome mec (SCCmec) type IVc. Phylogenic analysis by PFGE and WGS revealed close relatedness of all strains, with the number of single nucleotide polymorphisms ranging from 35 to 119 by WGS. Out of the ten strains, nine possessed the genomic island SaPISaitama2 containing tst, sec and sel genes. SaPISaitama2 comprises a mosaic of genomic islands SaPIm4 and SaPIm1 harbored by a hospital-associated MRSA strain Mu50. This study describes a regional outbreak of ST834-related CA-MRSA in children with a unique pathogenicity island in Japan. Pediatric patient tropism of this clone could be enhanced by susceptibility to fluoroquinolones and tetracyclines, which cannot be prescribed to children.

Sections du résumé

BACKGROUND BACKGROUND
Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infection has recently become a challenging problem worldwide and in Japan. We experienced 10 pediatric patients infected with CA-MRSA and hospitalized from 2011 to 2014 in a tertiary care hospital in Saitama, Japan, and assessed the characteristic of the strains using a whole genome sequencing (WGS)-based approach.
METHODS METHODS
CA-MRSA strains isolated from infected patients who required hospitalization for treatment were evaluated in this study. Antimicrobial susceptibility tests, molecular typing by PCR and pulse-field gel electrophoresis (PFGE) were performed to characterize MRSA strains. WGS was performed for detailed genetic analysis.
RESULTS RESULTS
A total of 582 MRSA strains (35.2%) were identified among 1625 S. aureus strains collected during the study period. Ten MRSA strains (1.7%) were defined as CA-MRSA clinically, and all were isolated from pediatric patients. All strains mainly caused purulent lymphadenitis, were susceptible to fluoroquinolone and tetracycline, exhibited sequence type (ST) 834 or its single-locus variants and contained staphylococcal cassette chromosome mec (SCCmec) type IVc. Phylogenic analysis by PFGE and WGS revealed close relatedness of all strains, with the number of single nucleotide polymorphisms ranging from 35 to 119 by WGS. Out of the ten strains, nine possessed the genomic island SaPISaitama2 containing tst, sec and sel genes. SaPISaitama2 comprises a mosaic of genomic islands SaPIm4 and SaPIm1 harbored by a hospital-associated MRSA strain Mu50.
CONCLUSIONS CONCLUSIONS
This study describes a regional outbreak of ST834-related CA-MRSA in children with a unique pathogenicity island in Japan. Pediatric patient tropism of this clone could be enhanced by susceptibility to fluoroquinolones and tetracyclines, which cannot be prescribed to children.

Identifiants

pubmed: 30626342
doi: 10.1186/s12879-018-3646-z
pii: 10.1186/s12879-018-3646-z
pmc: PMC6327381
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

35

Subventions

Organisme : Ministry of Education, Culture, Sports, Science and Technology (JP)
ID : S1201013
Organisme : St. Luke's Life Science Institute (JP)
ID : 2015-Research #27

Références

J Clin Microbiol. 1999 Oct;37(10):3411-4
pubmed: 10488222
Bioinformatics. 2000 Nov;16(11):1046-7
pubmed: 11159318
Lancet. 2001 Apr 21;357(9264):1225-40
pubmed: 11418146
JAMA. 2003 Dec 10;290(22):2976-84
pubmed: 14665659
Nucleic Acids Res. 2004 Jul 1;32(Web Server issue):W273-9
pubmed: 15215394
J Clin Microbiol. 2005 Jul;43(7):3364-72
pubmed: 16000461
Emerg Infect Dis. 2006 Apr;12(4):631-7
pubmed: 16704812
Antimicrob Agents Chemother. 2007 Jan;51(1):264-74
pubmed: 17043114
Lancet Infect Dis. 2006 Dec;6(12):753-5
pubmed: 17123892
J Microbiol. 2007 Oct;45(5):447-52
pubmed: 17978805
BMC Genomics. 2008 Feb 08;9:75
pubmed: 18261238
J Antimicrob Chemother. 2008 Aug;62(2):324-8
pubmed: 18467309
J Clin Microbiol. 2008 Oct;46(10):3246-58
pubmed: 18685010
J Antimicrob Chemother. 2009 Oct;64(4):680-3
pubmed: 19684078
J Clin Microbiol. 2009 Dec;47(12):4138-40
pubmed: 19812280
J Infect Chemother. 2010 Aug;16(4):292-7
pubmed: 20306108
J Infect Chemother. 2010 Aug;16(4):225-54
pubmed: 20336341
Clin Microbiol Rev. 2010 Jul;23(3):616-87
pubmed: 20610826
Ann Clin Microbiol Antimicrob. 2010 Nov 04;9:31
pubmed: 21050425
Am J Trop Med Hyg. 2011 Feb;84(2):313-7
pubmed: 21292906
Am J Infect Control. 2011 Dec;39(10):858-65
pubmed: 21658811
Int J Pediatr. 2011;2011:143872
pubmed: 22187567
J Clin Microbiol. 2012 Mar;50(3):573-9
pubmed: 22205805
J Clin Microbiol. 2012 Apr;50(4):1355-61
pubmed: 22238442
J Infect Chemother. 2012 Apr;18(2):228-40
pubmed: 22350401
PLoS One. 2012;7(2):e31245
pubmed: 22363594
N Engl J Med. 2012 Jun 14;366(24):2267-75
pubmed: 22693998
J Antimicrob Chemother. 2012 Nov;67(11):2640-4
pubmed: 22782487
BMC Microbiol. 2012 Jul 23;12:146
pubmed: 22823982
BMC Genomics. 2012 Sep 25;13:508
pubmed: 23009684
Lancet Infect Dis. 2013 Feb;13(2):130-6
pubmed: 23158674
BMC Infect Dis. 2013 May 11;13:214
pubmed: 23663295
APMIS. 2014 Jul;122(7):580-4
pubmed: 24106794
Infect Chemother. 2013 Jun;45(2):117-36
pubmed: 24265961
Nucleic Acids Res. 2014 Jan;42(Database issue):D206-14
pubmed: 24293654
J Clin Microbiol. 2014 May;52(5):1501-10
pubmed: 24574290
PLoS One. 2014 Aug 11;9(8):e104984
pubmed: 25110940
J Clin Microbiol. 2014 Dec;52(12):4305-8
pubmed: 25297335
MBio. 2015 Mar 10;6(2):e00054
pubmed: 25759497
Microb Drug Resist. 2015 Aug;21(4):441-7
pubmed: 25789579
J Infect Chemother. 2015 Sep;21(9):700-2
pubmed: 26091885
Genome Announc. 2015 Nov 12;3(6):null
pubmed: 26564052
J Antimicrob Chemother. 2018 Jan 1;73(1):33-40
pubmed: 29048488
J Clin Microbiol. 1995 Sep;33(9):2233-9
pubmed: 7494007
J Clin Microbiol. 1998 Sep;36(9):2548-53
pubmed: 9705390

Auteurs

Yuki Uehara (Y)

Department of Infection Control Science, Juntendo University Graduate School of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan. yuuehara@juntendo.ac.jp.
Department of Microbiology, Juntendo University Faculty of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan. yuuehara@juntendo.ac.jp.
Department of General Medicine, Juntendo University Faculty of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan. yuuehara@juntendo.ac.jp.

Takashi Sasaki (T)

Department of Microbiology, Juntendo University Faculty of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Infection Control Science Research Center, Juntendo University Graduate School of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.

Tadashi Baba (T)

Department of Microbiology, Juntendo University Faculty of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Infection Control Science Research Center, Juntendo University Graduate School of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.

Yujie Lu (Y)

Infection Control Science Research Center, Juntendo University Graduate School of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.

Eri Imajo (E)

Department of Laboratory Medicine, Saitama City Hospital, 2460, Mimuro, Midori-ku, Saitama, 336-8522, Japan.

Yuka Sato (Y)

Department of Laboratory Medicine, Saitama City Hospital, 2460, Mimuro, Midori-ku, Saitama, 336-8522, Japan.

Shigeru Tanno (S)

Department of Laboratory Medicine, Saitama City Hospital, 2460, Mimuro, Midori-ku, Saitama, 336-8522, Japan.

Munehiro Furuichi (M)

Division of Infectious Diseases, Department of Medical Subspecialties, National Center for Child Health and Development, 2-10-1, Okura, Setagaya-ku, Tokyo, 157-8535, Japan.

Miki Kawada (M)

Department of Infectious Diseases, Saitama City Hospital, 2460, Mimuro, Midori-ku, Saitama, 336-8522, Japan.

Keiichi Hiramatsu (K)

Department of Infection Control Science, Juntendo University Graduate School of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Department of Microbiology, Juntendo University Faculty of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Infection Control Science Research Center, Juntendo University Graduate School of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH